Published in Clin Pharmacol Ther on June 01, 2004
The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol (2011) 1.28
The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives. Cardiovasc J Afr (2010) 1.03
Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther (2012) 1.01
Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97? Biochemistry (2007) 0.96
Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos (2012) 0.89
Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J (2007) 0.83
Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival. Anticancer Res (2011) 0.81
Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity. J Pharm Biomed Anal (2014) 0.75
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. Pediatr Dermatol (2012) 2.00
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr (2007) 1.76
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68
Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci (2011) 1.67
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Cigarette smoking, stress-induced analgesia and pain perception in men and women. Pain (2005) 1.47
Effect of a vascular endothelial cadherin antagonist in a rat lung transplant model. Ann Thorac Surg (2013) 1.43
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol (2005) 1.33
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos (2006) 1.30
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther (2009) 1.21
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology (2004) 1.21
The Environmental Polymorphisms Registry: a DNA resource to study genetic susceptibility loci. Hum Genet (2008) 1.18
Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos (2007) 1.14
Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci (2010) 1.14
A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr (2006) 1.12
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab (2002) 1.10
Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system. Am J Public Health (2009) 1.09
Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (2010) 1.08
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
Growth failure in early life: an important manifestation of Turner syndrome. Horm Res (2002) 1.06
A method for fitting regression splines with varying polynomial order in the linear mixed model. Stat Med (2006) 1.05
An evaluation of HIV testing among inmates in the North Carolina prison system. Am J Public Health (2009) 1.05
P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res (2003) 1.05
Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. PLoS Negl Trop Dis (2012) 1.04
Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos (2008) 1.03
Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology (2010) 1.03
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci (2012) 1.02
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther (2012) 1.01
Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos (2004) 1.01
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr (2007) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis (2002) 1.00
Prediction of lung function response for populations exposed to a wide range of ozone conditions. Inhal Toxicol (2012) 0.98
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos (2004) 0.97
Ozone exposure-response model for lung function changes: an alternate variability structure. Inhal Toxicol (2013) 0.97
Effects of a prolonged standardized diet on normalizing the human metabolome. Am J Clin Nutr (2009) 0.96
Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology (2010) 0.95
Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos (2013) 0.94
Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos (2013) 0.93
Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res (2007) 0.93
Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr (2008) 0.93
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos (2007) 0.92
Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther (2004) 0.92
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation. J Exp Pharmacol (2010) 0.91
Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med (2010) 0.90
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos (2013) 0.90
Current challenges and controversies in drug-induced liver injury. Drug Saf (2012) 0.90
Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol (2007) 0.90
A new method for choosing sample size for confidence interval-based inferences. Biometrics (2003) 0.88
Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. J Pharmacol Exp Ther (2011) 0.88
Enhanced bioactivity of silybin B methylation products. Bioorg Med Chem (2012) 0.87
Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf (2014) 0.86
The temporal dynamics of ozone-induced FEV1 changes in humans: an exposure-response model. Inhal Toxicol (2007) 0.86
Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther (2002) 0.86
Predictive value of initial triage vital signs for critically ill older adults. West J Emerg Med (2013) 0.85
Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis. PLoS Negl Trop Dis (2013) 0.85
A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos (2013) 0.85
Methodology to assess clinical liver safety data. Drug Saf (2014) 0.84
CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv (2005) 0.84
Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol (2012) 0.84
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol (2002) 0.84
Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther (2004) 0.84
Human immunodeficiency virus type 1 RNA in breast-milk components. J Infect Dis (2003) 0.84
Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid Chromatography. Phytochem Anal (2013) 0.83
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol (2012) 0.83
Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol (2010) 0.83
Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab Dispos (2013) 0.83
Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. Drug Metab Dispos (2012) 0.82
Insight into hepatotoxicity: The troglitazone experience. Hepatology (2005) 0.82
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. Bioorg Med Chem (2013) 0.82
Influence of dietary substances on intestinal drug metabolism and transport. Curr Drug Metab (2010) 0.82